Font resize Email Print

Osamu Tetsu M.D., Ph.D.

Cancer and molecular biology

Osamu Tetsu M.D., Ph.D.

Dr. Tetsu has a proven long track record of cell signaling in  cancers. He discovered that cyclin D1 is a beta-catenin target gene, and that CDK2 kinase activity is dispensable in cancer cells, identified causative genes within the MAPK signaling pathway in cardio-facio-cutaneous syndrome, and determined the mechanism of cyclin D1 protein degradation. He also established credentials in translational head and neck cancer research. Among them, his findings in ACC cell-line cross-contamination were featured in an article of the Wall Street Journal in April 2012. The PBS/KQED Radio also broadcasted about the findings through their special program Quest in July and November 2012. More recently, his research interests have focused on EGFR TKI drug resistance in lung cancer.



Selected publications:

Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O. (2009). Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One: 4: e6040.

Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, Jordan RCK. (2010). Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia: 12: 708-717.

Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O. (2014) Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance. Transl Oncol:. 7:780-7.

Phuchareon J, McCormick F, Eisele DW, Tetsu O. (2015) EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A. 112:E3855-63.

Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. (2016) Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy: 61:223-235.